KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Capital Expenditures (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Capital Expenditures data on record, last reported at $861000.0 in Q4 2025.

  • For Q4 2025, Capital Expenditures fell 46.75% year-over-year to $861000.0; the TTM value through Dec 2025 reached $2.7 million, down 56.14%, while the annual FY2025 figure was $2.7 million, 56.14% down from the prior year.
  • Capital Expenditures reached $861000.0 in Q4 2025 per PACB's latest filing, up from -$86000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $4.9 million in Q4 2022 and bottomed at -$787000.0 in Q3 2024.
  • Average Capital Expenditures over 5 years is $2.0 million, with a median of $1.6 million recorded in 2021.
  • Peak YoY movement for Capital Expenditures: surged 4141.79% in 2021, then plummeted 194.82% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $2.8 million in 2021, then soared by 72.55% to $4.9 million in 2022, then tumbled by 58.73% to $2.0 million in 2023, then decreased by 20.11% to $1.6 million in 2024, then tumbled by 46.75% to $861000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $861000.0 in Q4 2025, -$86000.0 in Q3 2025, and $550000.0 in Q2 2025.